Genetically determined polymorphisms in drug oxidation
- 1 September 1986
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 6 (5), 1020-1032
- https://doi.org/10.1002/hep.1840060534
Abstract
No abstract availableThis publication has 100 references indexed in Scilit:
- The Polymorphic Oxidation of ??-Adrenoceptor AntagonistsClinical Pharmacokinetics, 1986
- Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidationKlinische Wochenschrift, 1985
- Genetically Determined Variability in Acetylation and Oxidation Therapeutic ImplicationsDrugs, 1985
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984
- Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugsLife Sciences, 1983
- Oxidation Phenotype — A Major Determinant of Metoprolol Metabolism and ResponseNew England Journal of Medicine, 1982
- Ethnic Differences in Drug MetabolismClinical Pharmacokinetics, 1982
- Defective Oxidation of DrugsClinical Pharmacokinetics, 1982
- Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamineXenobiotica, 1979
- Hypotensive response to debrisoquine and hydroxylation phenotypeLife Sciences, 1978